Aclarion Delivers Strong Q1 2026 Results with 196% Annual Scan Volume Growth Reflecting Accelerating Clinical Adoption
Aclarion reported accelerating clinical adoption of its Nociscan platform with Q1 scan volume growing 196% year-over-year and 64% sequentially, driven by new account activations and deeper utilization within existing sites. The company strengthened its financial position with $19.0 million in cash, no debt, and the announcement of a $2.5 million share repurchase program, providing a cash runway into the second half of 2027. Key upcoming catalysts include the interim readout of the CLARITY randomized trial in late 2026 and ongoing reimbursement discussions with U.S. payers following coverage by major U.K.
Key figures
- Guidance
- cash runway into the second half of 2027
- Revenue Yoy
- 196%
- Deal Value Usd
- 2500000
- Scan volume qoq growth
- 64%
- Shares outstanding basic
- 2444871
- Cash per share fully diluted
- $6.60
- Shares outstanding fully diluted
- 2882371
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.